StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

ZNTLBullishAnalyst Target Updateanalyst
Medium materiality6/10

Wedbush Upgrades Zentalis Pharmaceuticals to Outperform

Nov 10, 2026, 10:06 AM EST1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

The upgrade and substantial gap between the target and posted price are bullish, but the move already underway and the lack of supporting rationale warrant caution.

AI summary

What happened, with direct paths to the underlying reporting

Wedbush upgraded ZNTL to Outperform and set a $6 target versus the posted price of $1.74. Shares had already risen 12.93% since the signal.

  • Wedbush upgraded ZNTL to Outperform with a $6 target versus a posted price of $1.74.
  • Shares were up 12.93% since the signal.

Key facts

  1. 01

    Target: $6

  2. 02

    Posted price: $1.74

  3. 03

    Analyst firm: Wedbush

  4. 04

    Analyst: Robert Driscoll

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.